AIDS Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis Therapy
Isoniazid Hepatotoxicity Not Increased In Hepatitis C Patients
November 19th, 2001
by Michael Greer, senior medical writer - Liver damage associated with the tuberculosis drug isoniazid is not exacerbated in patients who are also infected with hepatitis or HIV, researchers say. "Treatment of latent Mycobacterium tuberculosis infection with isoniazid can cause hepatotoxicity, but the risk of isoniazid-associated hepatotoxicity among persons coinfected with hepatitis C virus (HCV) is unknown," according to Pankaj Sadaphal and colleagues at Johns Hopkins University in Baltimore, the Baltimore City Health Department, the New York Academy of Medicine's Center for Urban Epidemiologic Studies, and Virco Laboratories in Mechelen, Belgium. ...
Source: AIDS Weekly (2001-11-19)
|
